Drugs / MRZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02330562 | Apr 2015 → Jun 2021 | glioblastoma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02330562 ↗ |
| Action | Inhibit | “MRZ is a novel, second generation proteasome inhibitor” NCT02330562 ↗ |
| Route | Intravenous | “MRZ 10 minute IV infusion on Days 1, 8, and 15” NCT02330562 ↗ |